Rivaroxaban in patients with a recent acute coronary syndrome.

in The New England journal of medicine (2012), 366(1), 9-19

BACKGROUND: Acute coronary syndromes arise from coronary atherosclerosis with superimposed thrombosis. Since factor Xa plays a central role in thrombosis, the inhibition of factor Xa with low-dose ... [more ▼]

BACKGROUND: Acute coronary syndromes arise from coronary atherosclerosis with superimposed thrombosis. Since factor Xa plays a central role in thrombosis, the inhibition of factor Xa with low-dose rivaroxaban might improve cardiovascular outcomes in patients with a recent acute coronary syndrome. METHODS: In this double-blind, placebo-controlled trial, we randomly assigned 15,526 patients with a recent acute coronary syndrome to receive twice-daily doses of either 2.5 mg or 5 mg of rivaroxaban or placebo for a mean of 13 months and up to 31 months. The primary efficacy end point was a composite of death from cardiovascular causes, myocardial infarction, or stroke. RESULTS: Rivaroxaban significantly reduced the primary efficacy end point, as compared with placebo, with respective rates of 8.9% and 10.7% (hazard ratio in the rivaroxaban group, 0.84; 95% confidence interval [CI], 0.74 to 0.96; P=0.008), with significant improvement for both the twice-daily 2.5-mg dose (9.1% vs. 10.7%, P=0.02) and the twice-daily 5-mg dose (8.8% vs. 10.7%, P=0.03). The twice-daily 2.5-mg dose of rivaroxaban reduced the rates of death from cardiovascular causes (2.7% vs. 4.1%, P=0.002) and from any cause (2.9% vs. 4.5%, P=0.002), a survival benefit that was not seen with the twice-daily 5-mg dose. As compared with placebo, rivaroxaban increased the rates of major bleeding not related to coronary-artery bypass grafting (2.1% vs. 0.6%, P<0.001) and intracranial hemorrhage (0.6% vs. 0.2%, P=0.009), without a significant increase in fatal bleeding (0.3% vs. 0.2%, P=0.66) or other adverse events. The twice-daily 2.5-mg dose resulted in fewer fatal bleeding events than the twice-daily 5-mg dose (0.1% vs. 0.4%, P=0.04). CONCLUSIONS: In patients with a recent acute coronary syndrome, rivaroxaban reduced the risk of the composite end point of death from cardiovascular causes, myocardial infarction, or stroke. Rivaroxaban increased the risk of major bleeding and intracranial hemorrhage but not the risk of fatal bleeding. (Funded by Johnson & Johnson and Bayer Healthcare; ATLAS ACS 2-TIMI 51 ClinicalTrials.gov number, NCT00809965.). [less ▲]

Nikolai Neumaier

Book published by Fac. Sci. Technol. Commun. Univ. Luxemb., Luxembourg (2012)

Long-term follow-up of subthalamic nucleus stimulation in glucocerebrosidase-associated Parkinson's disease.

in Journal of neurology (2012), 259(9), 1970-2

« Le portfolio ». Apprendre à travers l’évaluation.

Scientific Conference (2012)

Philosophy of foreign language teaching within lifelong learning for medical specialists, Dans: et al (eds.), , : ,

in MASSARD, Gilbert (Ed.) Life-Long-Lerning Framework for Medical University Teaching Staff. The Collection of Articles (2012)

A Survey on Intersections of Maximal Partial Clones of Boolean Partial Functions

in Multiple-Valued Logic (ISMVL), 2012 42nd IEEE International Symposium on (2012)

We survey known results and present some new ones about intersections of maximal partial clones on a 2-element set.

Entre Attraction et Participation: Une Analyse Comparée du Discours Televisuel aux Expositions Universelles de Paris (1937), New York (1939) et Bruxelles (1958)

in Lugon, Olivier (Ed.) Expositions et Médias: Photograhie, Cinéma, Télévision (2012)

Visibly Audible. The Radio Dial as Mediating Interface

in Bijsterveld, Karin; Pinch, Trevor (Eds.) Oxford Handbook of Sound Studies (2012)

See-and-Avoid Quadcopter using Fuzzy Control Optimized by Cross-Entropy

in See-and-Avoid Quadcopter using Fuzzy Control Optimized by Cross-Entropy (2012)

In this work we present an optimized fuzzy visual servoing system for obstacle avoidance using an unmanned aerial vehicle. The cross-entropy theory is used to optimise the gains of our controllers. The ... [more ▼]

In this work we present an optimized fuzzy visual servoing system for obstacle avoidance using an unmanned aerial vehicle. The cross-entropy theory is used to optimise the gains of our controllers. The optimization process was made using the ROS-Gazebo 3D simulation with purposeful extensions developed for our experiments. Visual servoing is achieved through an image processing front-end that uses the Camshift algorithm to detect and track objects in the scene. Experimental flight trials using a small quadrotor were performed to validate the parameters estimated from simulation. The integration of cross-entropy methods is a straightforward way to estimate optimal gains achieving excellent results when tested in real flights. [less ▲]

Reducing congestion through persuasive gaming

Scientific Conference (2012)

In this paper we provide an overview of the I-GEAR (incentives and gaming environments for automobile routing) project that is intended to reduce traffic congestion in Luxembourg through the use of ... [more ▼]

In this paper we provide an overview of the I-GEAR (incentives and gaming environments for automobile routing) project that is intended to reduce traffic congestion in Luxembourg through the use of persuasive gaming. In order to illustrate some of the issues involved we also present an outline concept of a live game in which we propose to encourage the workshop participants to take part. If a sufficient number of workshop participants take part, this real life game could even be used as a small scale study within the project. [less ▲]